Dermira, Inc. (NASDAQ:DERM) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.04, Bloomberg Earnings reports. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1 million.

Shares of Dermira (NASDAQ:DERM) traded down 3.05% during trading on Tuesday, hitting $25.10. The company had a trading volume of 402,874 shares. Dermira has a 52 week low of $24.46 and a 52 week high of $38.75. The firm’s 50 day moving average is $29.16 and its 200-day moving average is $30.96. The stock’s market capitalization is $1.04 billion.

Several analysts have weighed in on DERM shares. Mizuho lowered their price target on Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Cantor Fitzgerald started coverage on Dermira in a report on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price target on the stock. Evercore ISI started coverage on Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price target on shares of Dermira in a report on Tuesday, July 18th. Five analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.80.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/08/dermira-inc-derm-releases-quarterly-earnings-results.html.

In related news, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $30.00, for a total value of $75,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $29.06, for a total value of $145,300.00. The disclosure for this sale can be found here. Insiders sold 16,812 shares of company stock worth $482,231 over the last quarter. 13.30% of the stock is owned by company insiders.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Earnings History for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.